GreenfieldAnalysis

Stock update for ADMA! +6.63% Today

Long
NASDAQ:ADMA   ADMA Biologics Inc
Stock update for ADMA! +6.63% Today

The stock symbol ADMA had a large market move today +6.63% that is close enough to my price target call of $2.12 on Dec 7, 2020 (please check my previous article on Dec 7, 2020). Remember what I said earlier, the stock must prove itself a winner by staying above $2.12. Currently, I have a short-term price target of $2.40. However, be careful of market volatility, I will remember to place a stop at $1.89. If the stock to trade lower than $1.80 on high volume, then there is a chance the bears will short sell the stock to the previous low of $1.55 or to a new low.

Just a humble market opinion by Greenfield Analysis. This is not a recommendation. Greenfield Analysis has no investment in ADMA, no plan to initiate a trade-in ADMA and does not receive any compensation for this market opinion. Please click like and follow to see more. Thank you for reading.


Greenfield
Comment:
Dec 9, 2020, A bullish continuation day for ADMA +6.22%
The stock ADMA opened the day with a gap above the previous day's high. Tested both price levels that I predicted $2.41 & $2.12. The stock ADMA today gained another +6.22%. My short-term price target is still $2.41. Remember previously I said, "The stock must prove itself a winner by reaching that price and staying above it." I think the stock is still very bearish, but bullish short-term. I will be very careful and remember to place a very tight stop loss.

Just a humble market opinion by Greenfield Analysis. This is not a recommendation. Greenfield Analysis has no investment in any of the securities mentioned in the article, no plan to initiate a trade in any of the securities mentioned, and does not receive any compensation for this market opinion. Please click Like and follow to see more. Thank you for reading.


Greenfield
Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.